Anil Veluvolu, MD
Hematology & Oncology · Shreveport, LANPI 1124174644
Payments from drug & device makers
Across 146 payments — averaging $6268.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$667K
- Ipsen Bioscience Inc.$222K
- Astrazeneca UK Limited$24K
- Novartis$349
- Novocure Inc.$262
- Sirtex Medical Inc$233
- plus $2K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $667,194 |
| Ipsen Bioscience Inc. | 9 | $221,546 |
| Astrazeneca UK Limited | 12 | $23,999 |
| Novartis | 19 | $349 |
| Novocure Inc. | 1 | $262 |
| Sirtex Medical Inc | 1 | $233 |
| Tempus AI, Inc | 9 | $195 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $183 |
| AbbVie | 7 | $174 |
| Daiichi Sankyo Inc. | 8 | $159 |
| Pfizer | 9 | $150 |
| Sanofi | 6 | $107 |
| Astellas Pharma US Inc | 4 | $90 |
| Myriad Genetic Laboratories, Inc. | 1 | $83 |
| Merck | 5 | $83 |
| Seagen Inc. | 1 | $83 |
| Johnson & Johnson | 5 | $69 |
| Amgen | 4 | $63 |
| GSK | 1 | $26 |
| Gilead | 2 | $25 |
| UCB, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Beigene USA, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Advanced Accelerator Applications | 1 | $13 |
How this compares
$915,229 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Shreveport
- Prakash PeddiShreveport$670K
- Gary BurtonShreveport$458K
- Kevin GallagherShreveport$339K
- Poornima RamadasShreveport$313K
- Richard MansourShreveport$281K
- Shashank CingamShreveport$271K
- Maxwell McDonaldShreveport$163K
- Kirtan KotichaShreveport$117K
- Joyce FeaginShreveport$95K
- Steven BoniolShreveport$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.